|
Reason for modification |
Overall |
d4T in regimen |
AZT in regimen |
| Drug Contraindication, IR (95% CI) |
10.3 per 100py (6.9-15.4) |
10 per 100py
(5.6-18.1) |
10.6 per 100py (6.1-18.2) |
| TB treatment |
18 |
6 |
12 |
| Pregnancy |
6 |
5 |
1 |
| Toxicity / Side-effects, IR (95% CI) |
5.9 per 100py (4.8-7.3) |
5.1 per 100py
(4-6.5) |
11 per 100py (7.2-16.7) |
| Peripheral neuropathy |
29 |
29 |
0 |
| Lipodystrophy / lipoatrophy |
27 |
26 |
1 |
| Anaemia |
6 |
0 |
6 |
| Hypersensitivity rash |
9 |
2 |
7 |
| Hepatitis / raised transaminases |
8 |
3 |
5 |
| Lactic acidosis |
3 |
3 |
0 |
| Vomiting |
2 |
0 |
2 |
| Myalgia |
1 |
0 |
1 |
| Treatment failure, IR (95% CI) |
4.9 per 100py (1.2-19.5) |
4.9 per 100py
(1.2-19.5) |
- |
| Treatment failure |
2 |
2 |
0 |
| Other reasons, IR (95% CI) |
53.3 per 100py (13.3-213.3) |
53.3 per 100py (13.3-213.3) |
- |
| Drug shortage |
2 |
2 |
0 |
| Total, IR (95% CI) |
1 per 100py (0.8-1.2) |
1.2 per 100py
(0.9-1.5) |
0.7 per 100py (0.5-1) |
| Total |
113 |
78 |
35 |
TB–tuberculosis; IR – Incidence rate; 95% CI – 95% Confidence interval; py – person years; d4T – Stavudine; AZT- Zidovudine. Totals for Drug contraindication (n=24,
21.2%); Toxicity (n=85, 75.2%); Treatment failure (n=2, 1.8%); Other reasons (n=2, 1.8%). |
